By Timothy S. Donahue

Top Takeaways:

• Federal Registrations: More than 900 medical marijuana dispensaries in seven states are receiving DEA registrations under Schedule III.
• Compliance Deadline: Qualifying businesses face a November 29 deadline to align their supply chains with federal requirements.
• Limited Reform: Recreational marijuana remains Schedule I, and businesses operating under combined licenses face additional barriers.

Medical marijuana is getting a federal green light. The fine print could be a buzzkill.

The U.S. Drug Enforcement Administration (DEA) has begun issuing federal registrations to more than 900 medical marijuana dispensaries in seven states, marking a significant step toward aligning state-licensed cannabis operations with federal law.

The Department of Justice announced the registrations on October 30, covering qualifying dispensaries in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia, and West Virginia.

The move follows an April 2026 rule that places certain state-authorized medical marijuana activities under Schedule III of the Controlled Substances Act. Recreational marijuana remains Schedule I.

“DEA’s decision to begin registering medical marijuana businesses is a positive and long-overdue development,” cannabis attorney Rod Kight wrote in an analysis. “For decades, state-licensed operators have faced the contradiction of being authorized under state law while remaining prohibited under federal law. This change begins to address that problem.”

The registrations establish a federal pathway for qualifying dispensaries, manufacturers, and distributors, although state licenses alone do not guarantee federal approval. The DEA has begun registering dispensaries and is reviewing applications from manufacturers and distributors.

The transition also entails significant compliance requirements.

Under guidance issued October 30, businesses that submitted complete applications between April 28 and June 26 may qualify for temporary authorization while their applications are pending. However, they may generally conduct Schedule III marijuana transactions only with other qualifying applicants or federally registered businesses.

The DEA expects those businesses to establish compliant supply chains by November 29. Transactions with unqualified suppliers or customers may result in registration denials or revocations.

“However, the new supply-chain restrictions could disrupt established businesses and potentially limit patient access,” Kight warned.

The agency has provided limited relief to qualifying dispensaries and distributors holding inventory acquired before October 30, but that accommodation generally does not authorize additional purchases from unregistered suppliers.

Testing laboratories pose another obstacle. The DEA has outlined limited enforcement discretion for required testing at certain unregistered in-state laboratories when appropriately registered facilities are unavailable.

Businesses in states with recreational marijuana markets face additional uncertainty. In an October 30 action involving a Minnesota dispensary, the DEA cited the state’s dual-purpose licensing system as the basis for denying federal registration.

The distinction could affect businesses operating under combined medical and recreational licenses, although the eligibility of separately licensed medical-only operations in those states remains unclear.

The shift to Schedule III could also yield substantial tax benefits. Internal Revenue Code Section 280E limits ordinary business deductions for activities involving Schedule I and II substances, potentially allowing qualifying medical marijuana operations to claim deductions previously unavailable.

However, federal registration does not constitute U.S. Food and Drug Administration authorization, generally authorize interstate marijuana commerce, or guarantee access to banking.

Kight said the changes are welcome but do not resolve the industry’s broader legal problems.

“I continue to believe that Congress should remove cannabis from the Controlled Substances Act and establish reasonable federal standards that protect consumers while allowing legitimate businesses to operate and compete,” he wrote.

“Schedule III is progress, but it is far from being a substitute for comprehensive cannabis reform.”